ArticleAntimicrobial agents and chemotherapy2018
Ceftaroline Resistance by Clone-Specific Polymorphism in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Breaking the antimicrobial resistance dilemma: marine natural products, a treasure trove for the development of new anti-Marine life science & technology · 2026Review
- BeyondAntimicrobial agents and chemotherapy · 2026Article
- Use of Ceftaroline for prosthetic joint infections and spinal hardware infections.Journal of clinical orthopaedics and trauma · 2025Article
- Ceftaroline Exhibits PromisingInternational journal of microbiology · 2025Article
- Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?Pathogens (Basel, Switzerland) · 2024Review
- Beyond the Wild MRSA: Genetic Features and Phylogenomic Review ofMicroorganisms · 2023Review
- Evaluation of In-Vitro Activity of Ceftaroline Against Methicillin-Resistant Staphylococcus aureus Clinical Isolates.Cureus · 2023Article
- Molecular Determinants of β-Lactam Resistance in Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- Article
- Targeted Therapy of Severe Infections Caused byMicroorganisms · 2023Article
- Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints.Ethiopian journal of health sciences · 2023Article
- Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation.Antimicrobial agents and chemotherapy · 2022Article
- Molecular Mechanisms of Drug Resistance inInternational journal of molecular sciences · 2022Review
- Antimicrobial Resistance and Clonal Lineages ofMicroorganisms · 2022Article
- Study on Demethoxycurcumin as a Promising Approach to Reverse Methicillin-Resistance ofInternational journal of molecular sciences · 2021Article
- Ability of Bicarbonate Supplementation To Sensitize Selected Methicillin-ResistantAntimicrobial agents and chemotherapy · 2020Article
- Using genomics to understand meticillin- and vancomycin-resistantMicrobial genomics · 2020Review
- Antimicrobial resistance in methicillin-resistantAntimicrobial agents and chemotherapy · 2019Review
- A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage.Journal of clinical microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A total of 281 nonduplicated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.